Immunoepigenetics: A Future Sentinel for Tumor Directed Therapies
A special issue of International Journal of Molecular Sciences (ISSN 1422-0067). This special issue belongs to the section "Molecular Oncology".
Deadline for manuscript submissions: closed (31 October 2020) | Viewed by 13035
Special Issue Editors
Interests: DNA damage and repair; DNA structure-induced genetic instability; mechanisms of mutagenesis; cancer etiology
Special Issue Information
Dear Colleagues,
Both genetic and environmental factors are known to influence immune responses, particularly in disease. This is often due to epigenetic changes in the host, which modulate the differentiation and function of immune cells. Pathogen-derived factors (e.g., live viral particles) resulting from virotherapy and excessive use of TLR ligands (TLR mimicry) can contribute to alterations in the expression of key pathways, such as those involving IRF, STAT, TGF, TLRs, and HLA genes, which are paramount for proper functioning of the immune system. Alterations in the expression, splicing, and re-arrangement of various genes and in translation can contribute to autoimmunity. Epigenetic modifications of genes involved in the immune response can often render immune cells incapable of combating tumors. Recent studies have implicated epigenetic changes in the genes coding for CD40-40L, CD80, CD86, and ICAM-1 antigens and death-inducing receptors (e.g. PD-1) for the inability of these molecules to activate immune responses and control tumor growth. Therefore, control of epigenetic changes in the host by the use of drugs targeting DNA methyltransferases and HDACs and of probiotics is believed to hold potential for stimulating host immune responses and eradicating tumors. The major aim and scope of this Special Issue is to discuss various recent modalities for the design of therapeutics to mitigate epigenetic changes for improved cancer therapies.
Prof. Dr. Karen M. Vasquez
Dr. Hridayesh Prakash
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. International Journal of Molecular Sciences is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. There is an Article Processing Charge (APC) for publication in this open access journal. For details about the APC please see here. Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- Immune-editing and tumor relapse
- Histone modification and chemo/radioresistance
- TLR polymorphism and immune evasion
- HLA polymorphism and autoimmunity
- Epigenesis and bystander toxicities
